Optimised electronic patient records to improve clinical monitoring of HIV-positive patients in rural South Africa (MONART trial): study protocol for a cluster-randomised trial.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
20 Dec 2021
Historique:
received: 15 11 2021
accepted: 06 12 2021
entrez: 21 12 2021
pubmed: 22 12 2021
medline: 24 12 2021
Statut: epublish

Résumé

There is poor viral load monitoring (VLM) and inadequate management of virological failure in HIV-positive individuals on antiretroviral therapy in rural KwaZulu-Natal, South Africa. This could be contributing to increasing HIV drug resistance in the setting. This study aims to investigate the clinical and process impediments in VLM within the health system and to evaluate a quality improvement package (QIP) to address the identified gaps. The QIP comprises (i) a designated viral load champion responsible for administrative management and triaging of viral load results (ii) technological enhancement of the routine clinic-based Three Interlinked Electronic Register (TIER.Net) to facilitate daily automatic import of viral load results from the National Health Service Laboratory to TIER.Net (iii) development of a dashboard system to support VLM. The study will evaluate the effectiveness of the QIP compared to current care for improving VLM and virological suppression using an effectiveness implementation hybrid type 3 design. This will use a cluster-randomised design with the primary healthcare clinics as the unit of randomisation with ten clinics randomised in a 1:1 ratio to either the intervention or control arm. We will enrol 150 HIV-positive individuals who had been on ART for ≥ 12 months from each of the ten clinics (750 in 5 intervention clinics vs. 750 in 5 control clinics) and follow them up for a period of 12 months. The primary outcome is the proportion of all patients who have a viral load (VL) measurement and are virally suppressed (composite outcome) after 12 months of follow up. Secondary outcomes during follow up include proportion of all patients with at least one documented VL in TIER.Net, proportion with VL ≥ 50 copies/mL, proportion with VL ≥ 1000 copies/mL (virological failure) and subsequent switch to second-line ART. We aim to provide evidence that a staff-centred quality improvement package, designated viral load monitoring champion, and augmentation of TIER.Net with a dashboard system will improve viral load monitoring and lead to improved virological suppression. This trial is registered on ClinicalTrials.gov on 8 Oct 2021. Identifier: NCT05071573; https://clinicaltrials.gov/ct2/show/NCT05071573?term=NCT05071573&draw=2&rank=1.

Sections du résumé

BACKGROUND BACKGROUND
There is poor viral load monitoring (VLM) and inadequate management of virological failure in HIV-positive individuals on antiretroviral therapy in rural KwaZulu-Natal, South Africa. This could be contributing to increasing HIV drug resistance in the setting. This study aims to investigate the clinical and process impediments in VLM within the health system and to evaluate a quality improvement package (QIP) to address the identified gaps. The QIP comprises (i) a designated viral load champion responsible for administrative management and triaging of viral load results (ii) technological enhancement of the routine clinic-based Three Interlinked Electronic Register (TIER.Net) to facilitate daily automatic import of viral load results from the National Health Service Laboratory to TIER.Net (iii) development of a dashboard system to support VLM.
METHODS/DESIGN METHODS
The study will evaluate the effectiveness of the QIP compared to current care for improving VLM and virological suppression using an effectiveness implementation hybrid type 3 design. This will use a cluster-randomised design with the primary healthcare clinics as the unit of randomisation with ten clinics randomised in a 1:1 ratio to either the intervention or control arm. We will enrol 150 HIV-positive individuals who had been on ART for ≥ 12 months from each of the ten clinics (750 in 5 intervention clinics vs. 750 in 5 control clinics) and follow them up for a period of 12 months. The primary outcome is the proportion of all patients who have a viral load (VL) measurement and are virally suppressed (composite outcome) after 12 months of follow up. Secondary outcomes during follow up include proportion of all patients with at least one documented VL in TIER.Net, proportion with VL ≥ 50 copies/mL, proportion with VL ≥ 1000 copies/mL (virological failure) and subsequent switch to second-line ART.
DISCUSSION CONCLUSIONS
We aim to provide evidence that a staff-centred quality improvement package, designated viral load monitoring champion, and augmentation of TIER.Net with a dashboard system will improve viral load monitoring and lead to improved virological suppression.
TRIAL REGISTRATION BACKGROUND
This trial is registered on ClinicalTrials.gov on 8 Oct 2021. Identifier: NCT05071573; https://clinicaltrials.gov/ct2/show/NCT05071573?term=NCT05071573&draw=2&rank=1.

Identifiants

pubmed: 34930182
doi: 10.1186/s12879-021-06952-5
pii: 10.1186/s12879-021-06952-5
pmc: PMC8686584
doi:

Banques de données

ClinicalTrials.gov
['NCT05071573']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1266

Subventions

Organisme : Royal Academy of Engineering
ID : FF\1920\1\23

Informations de copyright

© 2021. The Author(s).

Références

Public Health Action. 2018 Dec 21;8(4):225-231
pubmed: 30775284
PLoS One. 2007 Jan 17;2(1):e152
pubmed: 17225857
J Int AIDS Soc. 2014 Apr 28;17:18908
pubmed: 24780511
Sci Transl Med. 2017 Dec 13;9(420):
pubmed: 29237762
BMJ. 2012 Sep 04;345:e5661
pubmed: 22951546
HIV Med. 2020 Aug;21(7):457-462
pubmed: 32495515
Int J Epidemiol. 2021 Mar 3;50(1):33-34
pubmed: 33437994
AIDS Res Hum Retroviruses. 2016 Aug;32(8):763-9
pubmed: 27002368
AIDS. 2005 Jan 3;19(1):1-14
pubmed: 15627028
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2019 Jul 2;69(2):207-214
pubmed: 30321314
Antivir Ther. 2008;13 Suppl 2:25-36
pubmed: 18575189
Nat Commun. 2020 Dec 1;11(1):5922
pubmed: 33262331
EClinicalMedicine. 2019 Mar 18;9:26-34
pubmed: 31143879
AIDS. 2014 Mar;28 Suppl 2:S161-9
pubmed: 24849476
Lancet Infect Dis. 2016 May;16(5):565-575
pubmed: 26831472

Auteurs

Collins Iwuji (C)

Department of Global Health Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, BN1 9PX, UK. c.iwuji@bsms.ac.uk.
Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa. c.iwuji@bsms.ac.uk.

Meg Osler (M)

Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Lusanda Mazibuko (L)

Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.

Natalia Hounsome (N)

Department of Global Health Infection, Brighton and Sussex Medical School, University of Sussex, Falmer, Brighton, BN1 9PX, UK.

Nothando Ngwenya (N)

Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.

Rujeko Samanthia Chimukuche (RS)

Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.

Thandeka Khoza (T)

Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.

Dickman Gareta (D)

Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.

Henry Sunpath (H)

Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Andrew Boulle (A)

Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Department of Health, Provincial Government of the Western Cape, Cape Town, South Africa.

Kobus Herbst (K)

Africa Health Research Institute, Durban, KwaZulu-Natal, South Africa.
DSI-MRC South African Population Research Infrastructure Network, Durban, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH